CLINICAL CORNER

CLINICAL CORNER

According to experts interviewed by MM&M, companies are taking a targeted biologic approach to developing these drugs. [...]this is a Big Pharma-not biotech-phenomenon, points out Tim Anderson, the Bernstein Research analyst, and Bernard Tisserand, VP for respiratory clinical development, INC Re...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medical Marketing and Media 2014-04, Vol.49 (4), p.42
1. Verfasser: Tisserand, Bernard
Format: Artikel
Sprache:eng
Schlagworte:
Asthma
Disease
Drug dosages
Monoclonal antibodies
Patients
Pharmaceutical industry
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:According to experts interviewed by MM&M, companies are taking a targeted biologic approach to developing these drugs. [...]this is a Big Pharma-not biotech-phenomenon, points out Tim Anderson, the Bernstein Research analyst, and Bernard Tisserand, VP for respiratory clinical development, INC Research.
ISSN:0025-7354